Business Context and Reporting Period
Company: BioSig Technologies, Inc. (Note: Request metadata listed "Streamex Corp.", but filing text identifies BioSig Technologies, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 20, 2019 (Event Date); November 26, 2019 (Signature Date)
Business Context: The Company entered into three separate patent and know-how license agreements with the Mayo Foundation for Medical Education and Research ("Mayo") covering electrophysiology software, electrophysiology systems, and stimulation/electroporation technologies for various medical treatments.
Key Financial Metrics and Transaction Terms
The filing details specific financial obligations and equity issuances related to the new agreements rather than standard periodic financial performance metrics (revenue, profit, cash flow).
- Upfront Cash Consideration: Total of $175,000 paid to Mayo ($25,000 for EP Software Agreement, $100,000 for Tools Agreement, $50,000 for NeuroClear Agreement).
- Milestone Payments: Potential aggregate payments of up to $1,875,000 ($625,000 + $550,000 + $700,000) contingent on future achievements.
- Royalties: Earned royalty payments on sales of licensed products and sublicense income.
- Equity Issuance (Warrants):
- EP Software Warrant: 284,455 shares of BioSig common stock at $6.16/share.
- Tools Warrant: 284,455 shares of BioSig common stock at $6.16/share.
- NeuroClear Warrant: 473,772 shares of NeuroClear Technologies, Inc. common stock at $5.00/share.
- Warrant Terms: 8-year duration, immediately exercisable, cashless exercise option available if no effective registration statement exists.
Material Changes Versus Prior Period
This filing reports a specific event (entry into material definitive agreements) rather than a comparative financial period. The material change is the acquisition of exclusive and non-exclusive licenses to Mayo's intellectual property in exchange for cash, future milestones, royalties, and equity warrants. No prior period financial data is provided in this document for comparison.
Guidance, Outlook, Risks, and Contingencies
- Outlook: The agreements grant the Company rights to develop, make, use, and sell licensed products in specific medical fields, potentially expanding its product portfolio.
- Risks and Contingencies:
- Termination: Agreements may be terminated by Mayo for material breach, insolvency of the Company, or if the Company initiates legal proceedings against Mayo (except for uncured breaches by Mayo).
- Dilution: Issuance of warrants for approximately 568,910 shares of BioSig common stock and 473,772 shares of NeuroClear common stock creates potential dilution.
- Future Obligations: The Company is contingent on future sales and milestones to pay up to $1.875 million in additional fees.
- Unregistered Securities: The warrants were issued in reliance on Section 4(a)(2) of the Securities Act of 1933 and were not registered.
Investor Verification Checklist
- Verify the current cash position of BioSig Technologies, Inc. to assess the impact of the $175,000 upfront payment.
- Review the specific definitions of "milestone events" in the agreements to evaluate the likelihood of the $1.875 million in potential future payments.
- Confirm the current share count and fully diluted share count to understand the dilution impact of the 568,910 BioSig warrants and 473,772 NeuroClear warrants.
- Assess the commercial viability and development timeline of the licensed technologies (electrophysiology software, systems, and stimulation/electroporation).
- Check for any existing registration statements or shelf registrations that would allow for cashless exercise of the warrants.